UnknownNCT05026021
Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia
Studying REN-related autosomal dominant tubulointerstitial kidney disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Principal Investigator
- Antoine DURRBACH, profesorHenri Mondor University Hospital
- Intervention
- Blood sample(biological)
- Enrollment
- 41 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (5)
- Henri Mondor Hospital (001), Créteil, France
- Saint Louis Hospital (003), Paris, France
- La Pitié Salpêtrière Hospital (004), Paris, France
- Necker Hospital (005), Paris, France
- Foch Hospital (002), Suresnes, France
Collaborators
SATT Paris Saclay
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05026021 on ClinicalTrials.govOther trials for REN-related autosomal dominant tubulointerstitial kidney disease
Additional recruiting or active studies for the same condition.
See all trials for REN-related autosomal dominant tubulointerstitial kidney disease →